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Abstract  
Vascular endothelial growth factor (VEGF) is the major endothelial mitogen in central nervous system 
neoplasms and it is expressed in 64-95% of glioblastomas (GBMs). Tumour cells are the main source of VEGF 
in GBMs whereas VEGF receptors (VEGFR-1, its soluble form sVEGFR-1, VEGFR-2 and neuropilin-1) are 
expressed predominantly by endothelial cells. Infiltrating tumour cells and newly-formed capillaries progress 
through the extracellular matrix by local proteolysis involving matrix metalloproteinases (MMPs). Recent 
studies have shown that VEGF expression and bioavailability can be modulated by MMPs. We reported 
previously that the expression of MTI-MMP in human breast cancer cells was associated with an enhanced 
VEGF expression. We used quantitative RT-PCR, Western blot, gelatin zymogra-phy and 
immunohistochemistry to study the expression of VEGF, VEGFR-1, VEGFR-2, sVEGFR-1, neuropilin-1, MTI-
MMP, MMP-2, MMP-9 and TIMP-2 in 20 human GBMs and 5 normal brains. The expression of these MMPs 
was markedly increased in most GBMs with excellent correlation between mRNA and protein levels; activated 
forms of MMP-2 and MMP-9 were present in 8/18 and 7/18 of GBMs. A majority of GBMs (17/20) also 
expressed high levels of VEGF, as previously reported, with strong correlation between VEGF and MTI-MMP 
gene expression levels, and double immunostain-ing showed that VEGF and MTI-MMP peptides co-localize in 
tumour and endothelial cells. Our results suggest that the interplay between metalloproteinases and VEGF 
previously described in experimental tumours may also be operative in human GBMs. Because of its dual ability 
to activate MMP-2 and to up-regulate VEGF, MTI-MMP might be of central importance in the growth of GBMs 
and represent an interesting target for anti-cancer treatments. 
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Angiogenesis is critical for the development of normal tissue and solid tumours. This process includes the 
degradation of the extracellular matrix (ECM) and the proliferation, migration and differentiation of endothelial 
cells, and is finely regulated by inhibitory and promoting factors.1,2 Among positive factors, vascular endothelial 
growth factor (VEGF) has been proposed as the major endothelial mitogen in central nervous system (CNS) 
neoplasms.3 Strong VEGF expression has been detected by immunohistochemistry in 64-95% of glioblastomas 
(GBMs).4-6 GBMs are the most common malignant primitive tumours of the CNS in adults.7 Microvascular 
proliferation is characteristic of these tumours and is an essential WHO diagnostic criteria.7 Tumour cells are the 
main source of VEGF in GBMs whereas VEGF receptors are predominantly expressed by endothelial cells.8,9 
These receptors differ both in terms of affinity and transduction signaling. 10-12 VEGFR-1 (flt-1) and VEGFR-2 
(flk/KDR) belong to the Class II tyrosine-kinase receptor family. VEGFR-1 has a soluble isoform (sVEGFR-1) 
that modulates VEGF availability.8,13 Neuropilin-1 (NRP1) is a co-receptor for VEGF that increases by 10-fold 
the affinity of the VEGF165 isoform for VEGFR-2.14 NRP1 is thought to modulate VEGF-mediated tumour 
angiogenesis in human malignant astrocytomas.10 The coordinated up-regulation of VEGF and its receptors 
appears as a critical event in the control of angiogenesis.8,12 
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Infiltrating tumour cells and newly-formed capillaries progress through the ECM by local proteolysis involving 
matrix metalloproteinases (MMPs).15,16 MMPs are proteolytic enzymes that are synthesized as inactive 
zymogens. Their activation requires the removal of a propeptide by proteinase cleavage and can be inhibited by 
various tissue inhibitors of MMPs (TIMPs). Most MMPs are secreted as soluble enzymes but a subset of them 
are inserted in the cell membrane by a transmembrane domain or by a glyco-sylphosphatatidyl-inositol anchor 
and are classified as membrane-type MMPs (MT-MMPs).17,18 In cultured tumour cells, MT-MMPs tend to 
accumulate on the cytoplasmic membrane of invadopodia where they selectively mediate local peri-cellular 
proteolysis. GBMs express high levels of MTI-MMP, MMP-2 and MMP-9.19,20 Among these MMPs, MTI-MMP 
might play a central role in the remodeling of the ECM as this membrane-bound protease is able to activate 
MMP-2 and MMP-13.21,22 Moreover, MTI-MMP has been shown to promote cell migration in various carcinoma 
cell lines by its ability to cleave laminin-5, a major constituent of basement membrane,23,24 and through the 
processing of CD44H (the major receptor for hyaluronan)25 and of αvβ3 integrin.26 
MTI-MMP is involved in both developmental and tumour angiogenesis.27 MTI-MMP overexpression in human 
melanoma cells has been associated with enhanced in vitro invasion and increased in vivo tumour growth and 
vascularization.28 We have shown previously that in MCF-7 breast cancer cells, VEGF transcription is 
upregulated when MTI-MMP is overexpressed.29 Up-regulation of VEGF by MTI-MMP has also been reported 
in a model of human glioma xenograft by Deryugina et al.30 These experimental data suggest a link between 
MTI-MMP and the VEGF network. We have tested for the presence of such a link in human glioblastomas. We 
compared the expression of VEGF and its receptors (VEGFR-1, sVEGFR-1,  VEGFR-2,  NRP1)  with MT1-
MMP, MMP-2, MMP-9 and TIMP-2 in a series of 20 GBMs and 5 normal brains. Using quantitative RT-PCR, 
gelatin zymog-raphy, Western blot and immunohistochemistry, we showed a strong correlation between the 
expression of VEGF, MT1-MMP, MMP-2 and MMP-9 in GBMs. These results are in accordance with previous 
in vitro studies and add to the evidence of interplay between VEGF and MMPs in the progression of human 
GBMs. 
MATERIAL AND METHODS  
Patients 
We studied 20 GBMs diagnosed at the Laboratory of Neuropa-thology-CHU Liège between 1997 and 2001. The 
series included 17 primary GBMs '(i.e., no previous history of lower grade diffuse astrocytoma) and 3 secondary 
GBMs (i.e., previous history of lower grade diffuse astrocytoma). Clinical information on these 20 cases have 
been reported previously as part of a larger series.31 The gender ratio was 1/1, and the age at time of diagnosis 
ranged from 41-79 years (mean 56 years). Normal brain cortex and white matter were obtained from 5 patients 
with intractable epilepsy treated by partial temporal lobectomy. Histological examination of these specimens 
showed severe hippocampal sclerosis; frozen tissue was sampled from microscopically normal inferior temporal 
gyri. Our study was approved by the Ethical Committee of the Faculty of Medicine of the University of Liège. 
RNA extraction and cDNA synthesis 
Total RNA was extracted from cryosections with RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany) 
according to the manufacturer's protocol. Total RNA (1 µg) was reverse transcribed with a ThermoScript reverse 
transcriptase (ThermoScript RT-PCR System, Invitrogen, Carlsbad, CA) and random hexamers as primers. 
Primers 
Primers pairs used in our study are described in Table I. Primers for the VEGF gene were chosen to distinguish 
between VEGF189, VEGF165, VEGF145 and VEGF121 mRNA isoforms. Intron-span-ning primers and probes for 
the TaqMan system (primers for VEGFR-1 (Flt-1), sVEGFR-1, VEGFR-2 (KDR/Flk-1) and NRP1) were 
designed to meet specific criteria by using Primer Express software (Perkin Elmer, Foster City, CA). All primers 
were synthesized by Eurogentec (Liège, Belgium). The 5'- and 3'-end nucleotides of the probe were labeled with 
a reporter (FAM = 6-carboxy-fluorescein) and a quencher dye (TAMRA = 6-car-boxy-tetramethylrhodamine). 
We conducted BLASTn (National Center for Biotechnology Information, Bethesda) searches against dbEST and 
the non redundant set of GenBank, EMBL, and DDBJ database sequences to confirm the total gene specificity of 
the nucleotide sequences chosen for the primers. The specificity of the amplified PCR products was confirmed 
either by restriction digest or by sequencing. The 18S ribosomal RNA was measured using the Pre-Developed 
TaqMan Assay Reagents Endogenous control kit from Applied Biosystems (Foster City, CA). 
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TABLE I-Sequence of primers and TaqMan probes used for RT-PCR studies 
Gene and 
accession number 
Position Sequence Size Cycles
MMP-2 FP 1740F 5 ' -AGATCTTCTTCTTC AAGGACCGGTT-3 ' 225 bp 33 
MMP-2-RP 
NM_004530 
1964R 5 ' -GGCTGGTC AGTGGCTTGGGGTA-3 '   
MMP-9-FP 1592F 5 ' -GCGG AG ATTGGGAACC AGCTGTA-3 ' 208 bp 37 
MMP-9-RP 
J05070 
1800R 5 ' -G ACGCGCCTGTGTACACCC AC A-3 '   
MMP-14-FP 1288F 5 ' -GGATACCC AATGCCCATTGGCC A-3 ' 221 bp 32 
MMP-14-RP 1508R 5 ' -CC ATTGGGC ATCCAGAAG AGAGC-3 '   
NM_004995     
TIMPl-FP 78F 5 ' -C ATCCTGTTGTTGCTGTGGCTG AT-3 ' 168 bp 33 
TIMPl-RP 245R 5'-GTCATCTTGATCTCATAACGCTGG-3'   
M12670     
TIMP-2-FP 78F 5 ' -CTCGCTGGACGTTGGAGGAAAGAA-3 ' 155 bp 30 
TIMP-2-RP 245R 5 ' -AGCCCATCTGGTACCTGTGGTTCA-3 '   
NM 003255     
VEGF-FP 1208F 5 ' -CCTGGTGGACATCTTCC AGGAGTA-3 ' 479 bp 33 
VEGF-RP 1687R 5 ' -CTCACCGCCTCGGCTTGTC ACA-3 ' 407 bp  
AH001553   347 bp 275 bp  
28S rRNA-RP 12403F 5 ' -GTTC ACCCACTAATAGGGAACGTG A-3 ' 212 bp 19 
28S rRNA-RP 
U13369 
12614R 5 ' -G ATTCTG ACTTAGAGGCGTTC AGT-3 '   
VEGFR1-FP 243 8F 5 ' -TCCCTTATG ATGCC AGC AAGT-3 ' 79 bp 40 
VEGFR1-RP 2516R 5 ' -CC AAAAGCCCCTCTTCC AA-3 '   
VEGFR1 Probe 
AF063657 
2469 5 ' -CCGGGAGAG ACTTAAACTGGGCAAATCA-3 '   
sVEGFRl-FP 2209F 5 ' -AC AATC AGAGGTG AGC ACTGC AA-3 ' 180 bp 40 
sVEGFRl-RP 2388R 5 ' -TCCG AGCCTGAAAGTTAGC AA-3 '   
sVEGFRl Probe 
U01134 
2257 5 ' -TCCAAATTTAAAAGCAC AAGG AATGATTGTACC AC-3 '   
VEGFR2-FP 791F 5 ' -CTTCGAAGC ATC AGCATAAGAAACT-3 ' 156 bp 40 
VEGFR2-RP 946R 5 ' -TGGTCATCAGCCCACTGGAT-3 '   
VEGFR2 Probe 
AF063658 
820 5 ' -AACCGAGACCTAAAAACCC AGTCTGGGAGT-3 '   
NRP1-FP 1831F 5 ' -C ACAGTGGAAC AGGTG ATG ACTTC-3 ' 112 bp 40 
NRP1-RP 1942R 5 ' -AACC ATATGTTGGAAACTCTG ATTGT-3 '   
NRP1 Probe 
XM 034725 
1883 5 ' -CC AC AG AAAAGCCC ACGGTCATAG AC A-3 '   
 
End point quantitative PCR for MT1-MMP, MMP-2, MMP-9, TIMP-2 mRNA and VEGF mRNA isoforms 
MT1-MMP, MMP-2, MMP-9, TIMP-2 and VEGF mRNA isoforms (VEGF189, VEGF165, VEGF145 and VEGF121) 
were measured in 10 ng aliquots of cDNA using Taq polymerase (Takara, Shiga, Japan) and 5 pmol of each 
primers (Table I). The thermal cycling conditions included 2 min at 95°C for denaturation and then amplification 
15 sec at 94°C, 20 sec at 66°C and 20 sec at 72°C (30 sec for VEGF isoforms) with a final incubation 2 min at 
72°C. PCR products were resolved on 2% Nusieve 3:1 agarose gels (BioWhittaker, Rockland, MD) and analyzed 
using a Fluor-S Multilmager (Bio-Rad, Hercules, CA) after ethidium bromide staining. Specific mRNA levels 
were expressed as the ratio of specific transcripts/28S transcripts. Experiments were repeated at least 3 times in 
duplicate. 
Real-time quantitative PCR for VEGFR-1, sVEGFR-1, VEGFR-2 and NRP1 mRNA 
Real-time quantitative RT-PCR analyses for VEGFR-1, sVEGFR-1, VEGFR-2, NRP1 mRNAs and 18S rRNA 
were carried out using the ABI PRISM 7700 Sequence Detection System instrument and software (PE Applied 
Biosystems). The sequences of the PCR primer pairs and fluorogenic probes that were used for each gene are 
shown in Table I. A standard curve was generated by 5-fold serial dilution of placenta cDNA to cover the range 
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of 50,000-80 ng and was run in duplicate during every experiment. For each experimental sample, the amount of 
target gene was determined from this standard curve. The relative expression level of the target gene was 
normalized against 18S rRNA to compensate for variation in the quality of RNA and the amount of input cDNA 
(as described by the manufacturer PE Applied Biosystems in User Bulletin 2). PCR was carried out with the 
TaqMan Universal PCR Master Mix (Applied Biosystems) using 5 µl of diluted cDNA (equivalent to 10 ng total 
RNA), 200 nM of the probe, and 400 nM primers in a 25 µl final reaction mixture. After a 2 min incubation at 
50°C to allow for UNG cleavage, AmpliTaq Gold was activated by an incubation for 10 min at 95°C. Each of 
the 40 PCR cycles consisted of 15 sec of denaturation at 95°C and hybridization of probe and primers for 1 min 
at 60°C. 
To confirm amplification specificity, the PCR products were also examined by subsequent 2% agarose gel 
electrophoresis. Experiments were repeated at least 3 times in duplicate. 
Immunohistochemistry for VEGF and MT1-MMP 
Sections (4 µm thick) were cut from formalin-fixed, paraffin embedded tumour tissue. They were hydrated 
through graded alcohols and incubated in H2O2 (0.3% 15 min). Sections were autoclaved for 11 min at 126°C in 
citrate buffer pH6 for antigen retrieval (Dako, Glostrup, Denmark). For double immunostaining sections were 
incubated in primary monoclonal Ab anti-MT1-MMP (Ab-4) 1:100 (Oncogene Research Products, San Diego, 
CA) followed by peroxidase-conjugated EnVision (Dako). Immu-noreactivity was visualized with 
3,3'diaminobenzidine (DAB + , Dako). Sections were then incubated with polyclonal Ab anti-VEGF 1:150 
(Santa Cruz, Santa Cruz, CA) for 1 hr at room temperature, followed by alkaline phosphatase-conjugated En-
Vision (Dako). Immunoreactivity for VEGF was visualized with Fast Red chromogenic substrate (Dako). Single 
immunostaining was also carried out on serial sections using each primary antibody alone with the 
corresponding enzyme-chromogene combination. Negative controls were obtained by omitting the primary 
antibodies. 
Gelatin zymography assay 
MMP-2 and MMP-9 activities were quantified by gelatin zymography on 2 normal brains and 18 GBMs. Ten 
cryosections (10 µM) were homogenized in buffer (0.1 M Tris-HCl pH 8.1, 0.4% Triton X-100) and centrifuged 
for 20 min at 5,000g. The pellets were discarded. 25 µg of total protein from homogenate superna-tants were 
mixed with non reducing sample buffer (62.5 mM Tris-HCl, pH 6.8; 2% SDS; 10% glycerol; 0.1% bromophenol 
blue) and electrophoresed directly on 10% SDS-polyacrylamide gels (SDS-PAGE) containing 0.1% gelatin 
(w/v).32 After electrophoresis, gels were washed for 1 hr at room temperature in a 2% (v/v) Triton X-100 
solution to remove SDS, transferred to a buffer (50 mM Tris-HCl, pH 7.6, containing 10 mM CaCl2) and 
incubated for 18 hr at 37°C. Gels were stained for 30 min with 0.1% (w/v) Coomassie brilliant blue G250 in 
45% (v/v) methanol/10% (v/v) acetic acid and destained in 10% (v/v) acetic acid/20% (v/v) methanol. Gels were 
analyzed with Quantity One software (version 4.2.2, Bio-Rad Laboratories, Hercules, CA) after densitomet-ric 
scanning of the gels using a Fluor-S Multimager (BioRad). 
Western blot 
MT1-MMP protein levels were analyzed in 2 normal brains and 15 GBMs. Brain extracts (25 µg) were mixed 
with 1/2 sample buffer [0.25 M Tris (pH6.8), 10% SDS (w/v), 4% sucrose (v/v), 5% β-mercaptoethanol (v/v) 
and 0.125% bromophenol blue (w/v)] and boiled for 5 min. They were separated on 10% SDS-PAGE gels and 
transferred to a PVDF filter (NEN, Boston, MA). After blocking with 5% milk (w/v), 0.1% tween 20 (w/v) in 
PBS for 2 hr at room temperature, membranes were exposed to the primary antibody (10 µg/ml, clone 113-5B7, 
Ab-4, Oncogene Research Products, San Diego, CA) at 4°C overnight followed by incubation with a horseradish 
peroxidase-conjugated rabbit anti-mouse antibody (1.3 µg/ml, Dako, Glostrup, Denmark). Signals were detected 
with an enhanced chemoluminescence (ECL) kit (NEN, Boston, MA). The relative intensities of the 
immunoreactive bands were analyzed with Quantity One software (version 4.2.2, Bio-Rad Laboratories) after 
densitometric scanning of the X-ray films using a Fluor-S Multimager (Bio-Rad). 
Statistics 
VEGF, VEGFRs, MMPs and TIMP-2 expression values in GBMs were correlated using Spearman's test. 
Correlation was considered significant for 2-tailed p>-value < 0.05. Statistical analysis was carried out using the 
Prism 3.0 software (GraphPad, San Diego, CA). 
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RESULTS  
Expression of VEGF and VEGF receptors 
VEGF mRNA was present in normal brains (295-375, arbitrary units; mean = 322) and in all GBM samples 
(217-5,112; mean = 1,774) as reported previously (Fig. 1).31 In most GBMs, VEGF mRNA levels were raised 2-
15-fold above normal brain values. The most abundant isoform in all cases was VEGF165, followed by VEGF121, 
VEGF189 and VEGF145 (data not shown). VEGFR-1 expression was found at similar levels in GBMs (89-357; 
mean = 182) and normal controls (154-198; mean = 181). There was no correlation between VEGFR-1 and 
VEGF mRNA levels (p = 0.35) in GBMs. VEGFR-2 was expressed in all GBMs (48-582; mean = 210) and in 
8/20 cases at least twice normal values (87-111; mean = 103). VEGF and VEGFR-2 expressions were correlated 
significantly (p = 0.0035) in GBMs. NRP1 expression varied broadly between GBMs (75-3,260; mean = 1,061) 
contrasting with a constant baseline expression in normal controls (383-397; mean = 390). In tumours, NRP1 
correlated with VEGFR-2 (p = 0.0119) but not with VEGF (p = 0.084), nor VEGFR-1 (p = 0.066). sVEGFR-1 
was expressed at low levels both in normal brains (84-92; mean = 87) and GBMs (25-208; mean = 101). 
sVEGFR-1, however, was found to correlate with VEGFR-1 (p = 0.0289), VEGFR-2 (p = 0.0029), and NRP1 (p 
= 0.0027) but not with VEGF (p = 0.053). 
 
FIGURE 1 - VEGF and VEGF receptors mRNA quantification: scatter of the distribution. Normal brain (black 
spots) and GBMs (white spots) mRNA levels are expressed as normalized values (as described in Material and 
Methods: A.U. = arbitrary units). Each point represents the mean of 3 separate experiments. 
 
 
Expression of MMPs and TIMP-2 
MT1-MMP, MMP-2 and MMP-9 were expressed in both normal brains and GBMs but at much higher levels in 
the latter (Fig. 2a). MT1-MMP mRNA levels were constantly higher in GBMs (34-202; mean = 106) than in 
normal controls (3-29; mean = 15). MMP-2 and MMP-9 mRNA levels were higher than controls in 18/20 and 
14/20 cases respectively (Fig. 2b) and correlated with each other (p = 0.0187). MT1-MMP mRNA levels 
correlated with MMP-2 (p = 0.0008) and MMP-9 (p = 0.005). TIMP-2 had a non-discriminative distribution in 
relation to the controls. TIMP-2 was correlated with MTl-MMP (p = 0.0019) and MMP-2 (p = 0.0002) but not 
Published in : International Journal of Cancer = Journal International du Cancer (2003) 
Status : Postprint (Author’s version) 
with MMP-9 (p = 0.1408). 
FIGURE 2 - MMPs and TIMP-2 mRNA quantification, (a) Representative 2% agarose gels of RT-PCR products 
for MT1-MMP, MMP-2, TIMP-2 and MMP-9 in 2 normal brains (NB) and 10 GBMs. (b) Scatter plots (as 
described in Fig. 1). Experiment was repeated at least 3 times in duplicate. 
 
 
Correlation between MTl-MMP protein and activated MMP-2 and -MMP-9 
By gelatin zymography, pro-MMP-2 and pro-MMP-9 were detected in the 18 GBMs and 2 controls examined 
(Fig. 3, Table II). In most GBMs, levels of these inactive forms were higher than in normal brains and were 
correlated with their respective mRNA levels (MMP2: p < 0.0001; MMP-9: p = 0.01) Activated forms of MMP-
2 and MMP-9 were not found in normal brain. By contrast, they were present in 8/18 (MMP-2) and 7/18 (MMP-
9) GBMs. MT1-MMP protein levels were quantified by Western blot in 15 GBMs and 2 normal brains (Fig. 4, 
Table II). They were significantly correlated with zymogram-derived activated MMP-2 levels (p = 0.0226) but 
not with activated MMP-9 levels (p = 0.06). Interestingly, MTl-MMP protein and mRNA levels were correlated 
significantly (p = 0.089), arguing for a predominantly transcriptional regulation in GBMs. 
 
TABLE II-Zymograms and western blot quantification of MMPS in normal brain and GBMs1 
 Gelatin  zymography Western blot 
 proMMP-9 MMP9 proMMP-2 MMP-2 MT1-MMP 
N1 0.41 0.00 1.52 0.00 0.44 
N2 0.28 0.00 0.83 0.00 0.47 
GB1 9.00 1.25 2.45 0.35 1.58 
Published in : International Journal of Cancer = Journal International du Cancer (2003) 
Status : Postprint (Author’s version) 
GB2 4.28 0.00 2.88 0.09 0.47 
GB3 1.67 0.00 2.86 0.00 0 
GB4 1.40 0.00 4.33 0.03 0 
GB5 0.47 0.00 1.15 0.00 ND 
GB7 5.29 0.00 1.12 0.00 0 
GB8 5.75 3.78 4.63 0.65 0.55 
GB9 5.02 0.00 4.09 0.00 0.45 
GB12 5.08 0.00 4.79 0.20 3.18 
GB13 6.86 4.58 4.93 0.48 1.55 
GB14 5.59 6.75 5.53 0.76 0.94 
GB15 8.00 0.00 5.13 0.00 ND 
GB16 5.55 1.10 5.66 0.00 2.50 
GB17 6.61 2.04 6.00 0.00 0 
GB18 14.79 4.34 8.20 0.40 1.97 
GB20 18.85 0.00 2.12 0.00 0 
GB21 16.52 0.00 2.37 0.00 ND 
GB22 20.66 0.00 5.11 0.00 0.86 
1Extracts expressed as arbitrary units. N, normal brain; GB, glioblastoma; ND, not determined. 
 
FIGURE 3 - Zymographic analysis of MMP-2 and MMP-9 in tissue extracts either from normal brain (N) or 
GBMs (GB). Medium conditioned by human HT1080 cells was included as positive control. Positions of pro-
MMP-9, MMP-9, pro-MMP-2 and MMP-2 are indicated by arrows. 
 
 
FIGURE 4 - Western blot analysis using the ab4 antibody (clone 113-5B7) raised against the catalytic domain of 
MT1-MMP. Protein extracts from MT1-MMP transfected A2058 cells (clone SI.5,28) were used as a positive 
control (+). MT1-MMP protein is detected in normal brain (N) and GBMs. 
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Correlation between VEGF network and MMPs 
mRNA levels of VEGF and VEGF receptors were compared to MT1-MMP, MMP-2, MMP-9 and TIMP-2 
(Table III). There was a significant correlation between VEGF expression and MT1-MMP, MMP-2 and MMP-9. 
A similar correlation was also observed between VEGFR-2 and MMPs. Interestingly, TIMP-2 expression was 
correlated with VEGF and VEGFR-2 but not with other VEGF receptors. 
 
TABLE III - Correlation between VEGF, VEGF receptors, MMPs and TIMP-2 expressed as p values derived 
from spearman's test 
 MTl-MMP MMP-2 MMP-9 TIMP-2 
VEGF 0.0250 0.0245 0.0053 0.0094 
VEGFR-1 0.0073 0.0710 <0.0001 0.4542 
VEGFR-2 <0.0001 0.0168 0.0004 0.0153 
NRP1 0.0053 0.1334 0.2457 0.5480 
s VEGFR-1 0.0313 0.0469 0.0194 0.2563 
 
Immunohistochemistry for VEGF and MTl-MMP 
VEGF immunoreactivity was shown in both tumour and endothelial cells, as previously reported (Fig. 5a,b).31 
By single immu-nostaining, MT1-MMP was detected in glioblastoma cells as a diffuse cytoplasmic staining 
(Fig. 5c,d). MT1-MMP positivity was also seen in endothelial cells and perivascular cells (Fig 5c). By double 
immunostaining, we observed the co-localization of VEGF and MT1-MMP in the cytoplasm of numerous 
tumour cells (Fig. 5e,f). 
 
FIGURE 5 - Immunohistochemis-try (scale bar = 50 µm). (a,b) VEGF positive tumour and endothelial cells 
(plain arrows) show granular red staining of the cytoplasm. Negative cells (empty arrow) are seen in their close 
vicinity, (c) MT1-MMP positive cells show a strong brown cytoplasmic staining. They include tumours cells 
(plain arrow) and endothelial cells (empty arrow), (d) MT1-MMP positive tumour cells (plain arrow) are mixed 
with negative cells (empty arrow), (e,f) Double staining with VEGF (red) and MT1-MMP1 (brown). Double 
positive tumour cells (plain arrows) contrast with negative or single weakly positive cell (empty arrow). 
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DISCUSSION 
GBMs are highly malignant tumours with poor prognosis. They show major microvascular proliferation and 
express high levels of VEGF.4-9 VEGF is a strong mitogen for endothelial cells thereby promoting angiogenesis. 
Previous reports33,34 have suggested that VEGF also stimulates tumour cell invasion, migration and survival in 
malignant epithelial cells through an autocrine loop by which overexpression of MMPs induces VEGF secretion 
and leads to subsequent amplification of cell proliferation and protection against apoptosis. We and others 
reported previously that in human melanoma and breast carcinoma cells, MT1-MMP upregulates VEGF 
expression whereas TIMP-2 reduces it.28,29,35 Therefore the pericellular proteolysis mediated by MT1-MMP in 
GBMs could also induce an autocrine loop resulting in enhanced VEGF expression. In turn, VEGF could act as a 
paracrine factor on endothelial cells to stimulate angiogenesis or possibly as an autocrine factor promoting 
glioblastoma cells survival-migration and invasion as demonstrated recently in the various tumour cell culture 
models. We compared the expression of VEGF and its receptors with MT1-MMP, MMP-2 and MMP-9 in 20 
GBMS and 5 normal brains. The expression of these MMPs was markedly increased in most GBMs with 
excellent correlation between mRNA and protein levels. MT1-MMP expression has been shown previously to 
correlate with glioma aggressiveness and its transfection in different tumour cell lines triggers an angiogenic 
phenotype and promotes tumour growth.20,28-30,36-38 A majority of GBMs (17/20) also expressed high levels of 
VEGF, as previously reported, with a strong correlation between VEGF and MT1-MMP gene expression levels. 
Double im-munostaining studies showed co-expression of VEGF and MT1-MMP by the same tumour cells. 
These data suggest that the transcriptional control of VEGF by MT1-MMP could be operative not only in vitro 
but also in vivo in human GBMs. 
MT1-MMP could also promote the growth of GBMs by its ability to activate MMP-2 in the presence of low 
concentration of TIMP-2.40 Pro-MMP-2 activation occurs after the formation of a ternary complex that contains 
pro-MMP-2 linked to cell surface MT1-MMP via a TIMP-2 bridge. In accordance with this hypothesis, we 
found that MMP-2 activation occurred in 8/18 of our GBMs20,41 among which 7/7 tested for MT1-MMP showed 
high contents of this protease. 
Activated MMP-9 was also found in 7/18 of our GBMs. This is an interesting finding as active MMP-9 is able to 
mobilize VEGF from its ECM reservoir.39 Therefore, MMPs could promote VEGF-mediated angiogenesis in 
GBMs by both transcriptional (MT1-MMP) and post translational (MMP-9) mechanisms. 
VEGF binding to VEGFR-2 triggers the proliferation and migration of endothelial cells whereas its binding to 
VEGFR-1 has opposite effects on glioblastoma cell lines.12,42 In our study, VEGF mRNA levels were correlated 
with VEGFR-2 but not VEGFR-1, NRP1 and sVEGFR-1. Collectively our data suggest that GBMs display a 
specific and complex pattern of VEGF receptors, transducing VEGF signaling toward cell proliferation and 
migration. 
In conclusion, our study adds to the evidence for an interplay between metalloproteinases and VEGF in human 
GBMs as previously documented in experimental tumours. Because of its dual ability to activate MMP-2 and to 
up-regulate VEGF, MT1-MMP might be of central importance in the growth of human glioblastomas and 
represent an interesting target for anti-cancer treatments. 
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